Identification of potential inhibitors against Staphylococcus aureus shikimate dehydrogenase through virtual screening and susceptibility test

References

• Guo Y, Song G, Sun M, Wang J, Wang Y. Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus. Front Cell Infect Microbiol. 2020;10:107.
   PubMed Web of Science ®Google Scholar
• Nichols CN, Wardlow LC, Coe KE, Sobhanie MME. Clinical outcomes with definitive treatment of methicillin-resistant Staphylococcus aureus bacteremia with retained daptomycin and ceftaroline combination therapy vs de-escalation to monotherapy with vancomycin, daptomycin, or ceftaroline. Open Forum Infect Dis. 2021;8(7):ofab327.
   PubMed Web of Science ®Google Scholar
• Silva V, Almeida F, Silva A, Correia S, Carvalho JA, Castro AP, Ferreira E, Manageiro V, Caniça M, Igrejas G, et al. First report of linezolid-resistant cfr-positive methicillin-resistant Staphylococcus aureus in humans in Portugal. J Glob Antimicrob Resist. 2019;17:323–325.
   PubMed Web of Science ®Google Scholar
• Mir R, Jallu S, Singh TP. The shikimate pathway: Review of amino acid sequence, function and three-dimensional structures of the enzymes. Crit Rev Microbiol. 2015;41(2):172–189.
   PubMed Web of Science ®Google Scholar
• Parish T, Stoker NG. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology (Reading)). 2002;148(Pt 10):3069–3077.
   PubMedGoogle Scholar
• Duque-Villegas MA, Lopes Abbadi B, Romero PR, Matter LB, Galina L, Dalberto PF, da Silva Rodrigues-Junior V, Ducati RG, Roth CD, Scheibler Rambo R, et al. EPSP synthase-depleted cells are aromatic amino acid auxotrophs in Mycobacterium smegmatis. Microbiol Spectr. 2021;9(3):e0000921.
   PubMed Web of Science ®Google Scholar
• Peek J, Lee J, Hu S, Senisterra G, Christendat D. Structural and mechanistic analysis of a novel class of shikimate dehydrogenases: evidence for a conserved catalytic mechanism in the shikimate dehydrogenase family. Biochemistr. 2011; 50(40):8616–8627.
   PubMed Web of Science ®Google Scholar
• Díaz-Quiroz DC, Cardona-Félix CS, Luis Viveros-Ceballos J, Reyes-González MA, Bolívar F, Ordoñez M, Escalante A. Synthesis, biological activity and molecular modelling studies of shikimic acid derivatives as inhibitors of the shikimate dehydrogenase enzyme of Escherichia coli. J Enzyme Inhib Med Chem. 2018;33(1):397–404.
   PubMed Web of Science ®Google Scholar
• Enríquez-Mendiola D, Téllez-Valencia A, Sierra-Campos E, Campos-Almazán M, Valdez-Solana M, Gómez Palacio-Gastélum M, Avitia-Domínguez C. Kinetic and molecular dynamic studies of inhibitors of shikimate dehydrogenase from methicillin-resistant Staphylococcus aureus. Chem Biol Drug Des. 2019;94(2):1504–1517.
   PubMed Web of Science ®Google Scholar
• Isa A, Majumdar S, Haider S. In Silico Identification of potential inhibitors against shikimate dehydrogenase through virtual screening and toxicity studies for the treatment of tuberculosis. Int Microbiol. 2019;22 (1):7–17.
   PubMed Web of Science ®Google Scholar
• Zhu N, Wang X, Li D, Lin Y, You X, Jiang J, Xu Y, Jiang W, Si S. IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis. Sci Rep. 2018; 8 (1):17439.
   PubMedGoogle Scholar
• Fonseca IO, Magalhães MLB, Oliveira JS, Silva RG, Mendes MA, Palma MS, Santos DS, Basso LA. Functional shikimate dehydrogenase from Mycobacterium tuberculosis H37Rv: purification and characterization. Protein Expr Purif. 2006;46(2):429–437.
   PubMed Web of Science ®Google Scholar
• Han C, Hu T, Wu D, Qu S, Zhou J, Ding J, Shen X, Qu D, Jiang H. X-ray crystallographic and enzymatic analyses of shikimate dehydrogenase from Staphylococcus epidermidis. FEBS J. 2009; 276(4):1125–1139.
   PubMed Web of Science ®Google Scholar
• Avitia-Domínguez C, Sierra-Campos E, Salas-Pacheco JM, Nájera H, Rojo-Domínguez A, Cisneros-Martínez J, Téllez-Valencia A. Inhibition and biochemical characterization of methicillin-resistant Staphylococcus aureus shikimate dehydrogenase. Molecules. 2014;19(4):4491–4509.
   PubMed Web of Science ®Google Scholar
• Wei B, Zhang T, Wang P, Pan Y, Li J, Chen W, Zhang M, Ji Q, Wu W, Lan L, et al. Anti-infective therapy using species-specific activators of Staphylococcus aureus ClpP. Nat Commun. 2022;13(1):6909.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun L, Ba X, Jiang S, Zhuang H, Zhu F, Wang H, Lan P, Shi Q, Wang Z, et al. Epidemiology, evolution and cryptic susceptibility of methicillin-resistant Staphylococcus aureus in China: a whole-genome-based survey. Clin Microbiol Infect. 2022; 28(1):85–92.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhang Q, Shi J, Zhu J W. Underestimated noncovalent interactions in protein data bank. J Chem Inf Model. 2019; 59(8):3389–3399.
   PubMed Web of Science ®Google Scholar
• Ray M, Sarkar S, Rath SN. Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2. Genomics Inform. 2020; 18(4):e43.
   PubMedGoogle Scholar
• Henrique Santana Silveira P, Silva da Rocha Pita S. Druggable sites identification in Streptococcus mutans VicRK system evaluated by catechols. J Biomol Struct Dyn. 2023;41(21):12000–12015.
   PubMedGoogle Scholar
• Khan N, Mukhtar H. Tea polyphenols in promotion of human health. Nutrients. 2018;11(1):39.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li J, Li Y, Liu Z, Lin Y, Huang JA. Anti-melanogenic effects of epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG) and gallocatechin-3-gallate (GCG) via down-regulation of cAMP/CREB/MITF signaling pathway in B16F10 melanoma cells. Fitoterapia. 2020; 145:104634.
   PubMed Web of Science ®Google Scholar
• Bo Z, Zhu J, Guo M, Zhang C, Cao Y, Zhang X, Yantao W. Gallocatechin gallate inhibits the replication of pseudorabies virus via suppressing the entry and release stages in its replication cycle. Vet Sci. 2023; 10(3):18.
   Google Scholar
• Xiao T, Cui M, Zheng C, Zhang P, Ren S, Bao J, Dandi G, Ronghao S, Ming W, Jianping L, et al. Both baicalein and gallocatechin gallate effectively inhibit SARS-CoV-2 replication by targeting Mpro and sepsis in mice. Inflammation. 2022;45(3):1076–1088.
   PubMed Web of Science ®Google Scholar
• Ko S, Jang WS, Jeong JH, Ahn JW, Kim YH, Kim S, Hyeon Kyeong C, Seungsoo C. (-)-Gallocatechin gallate from green tea rescues cognitive impairment through restoring hippocampal silent synapses in post-menopausal depression. Sci Rep. 2021; 11(1):910.
   PubMed Web of Science ®Google Scholar
• Park DH, Park JY, Kang KS, Hwang GS. Neuroprotective effect of gallocatechin gallate on glutamate-induced oxidative stress in hippocampal HT22 cells. Molecules. 2021; 26(5):1387.
   PubMed Web of Science ®Google Scholar
• Ikeda A, Iso H, Yamagishi K, Iwasaki M, Yamaji T, Miura T, Sawada N, Inoue M, Tsugane S, the JPHC Study Group. Plasma tea catechins and risk of cardiovascular disease in middle-aged Japanese subjects: The JPHC study. Atherosclerosis. 2018; 277:90–97.
   PubMed Web of Science ®Google Scholar
• Gabr GA, Hassan HMM, Seshadri VD, Hassan NMM. Comparative study of phenolic profile, antioxidant and antimicrobial activities of aqueous extract of white and green tea. Z Naturforsch C J Biosci. 2020; 77(11-12):483–492.
   Web of Science ®Google Scholar
• Javadkhani A, Shokouhi B, Mosayebzadeh A, Safa S, Fahimi M, Sharifi S, Maleki Dizaj S, Salatin S. Nano-catechin gel as a sustained release antimicrobial agent against clinically isolated Porphyromonas gingivalis for promising treatment of periodontal diseases. J Biomedicines. 2023; 11(7):1932.
   PubMed Web of Science ®Google Scholar
• Hui X, Hua SH, Wu QQ, Li H, Gao WY. Antimicrobial mechanism of epigallocatechin gallate and gallocatechin gallate: They target 1-deoxy-d-xylulose 5-phosphate reductoisomerase, the key enzyme of the MEP terpenoid biosynthetic pathway. Arch Biochem Biophys. 2017; 622:1–8.
   PubMed Web of Science ®Google Scholar
• Péter Zomborszki Z, Kúsz N, Csupor D, Peschel W. Rhodiosin and herbacetin in Rhodiola rosea preparations: additional markers for quality control? Pharm Biol. 2019; 57(1):295–305.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu J, Yan J, Xiao Y, Yang R, Huang R, Zhou J, Wang Z, Xiao W, Zheng C, et al. Systems pharmacology unravels the synergic target space and therapeutic potential of Rhodiola rosea L. for non-small cell lung cancer. Phytomedicine. 2020; 79:153326.
   PubMed Web of Science ®Google Scholar
• Döring K, Langeder J, Duwe S, Tahir A, Grienke U, Rollinger JM, Schmidtke M. Insights into the direct anti-influenza virus mode of action of Rhodiola rosea. Phytomedicine. 2022; 96:153895.
   PubMed Web of Science ®Google Scholar
• Zhou J-T, Li C-Y, Wang C-H, Wang Y-F, Wang X-D, Wang H-T, Zhu Y, Jiang M-M, Gao X-M. Phenolic compounds from the roots of Rhodiola crenulata and their antioxidant and inducing IFN-γ production activities. Molecules. 2015;20(8):13725–13739.
   PubMed Web of Science ®Google Scholar